ArticleCancers2026
Distinct Bone Marrow Metabolic Profiles at Relapse Compared with Initial Diagnosis in Pediatric Acute Lymphoblastic Leukemia-An LC-MS Metabolomics Study.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND/
objectivesRelapse remains the leading cause of mortality in pediatric acute lymphoblastic leukemia (ALL), underscoring the need for novel biomarkers and therapies. The objective of this study is to identify distinct metabolomes associated with relapsed ALL, using bone marrow aspirated at the relapse episode itself, a specimen that is rarely banked and whose metabolome has not previously been reported.
methodThis study utilized untargeted liquid chromatography-mass spectrometry (LC-MS) metabolomics on bone marrow aspirates from 21 children with B-lineage ALL. Aliquots from the 12 non-relapsed patients were collected at initial diagnosis and those from the 9 relapsed patients at relapse, so group and disease phase are collinear by design.
resultsThe resulting metabolic profile clearly distinguished bone marrow sampled at relapse from bone marrow sampled at initial diagnosis. Partial least-squares discriminant analysis separated the two groups, completely in positive ion mode and with 18 of 21 samples correctly classified in negative ion mode (1000-permutation test,
conclusionsThis exploratory comparison describes the metabolite composition of bone marrow at relapse and identifies fatty acid oxidation, the serine-glycine one-carbon pathway and ether-lipid metabolism as priorities for future investigation rather than as established therapeutic dependencies. Because the relapsed specimens were obtained at relapse, the signature describes relapsed disease and is not evidence that relapse can be predicted at diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.